Академический Документы
Профессиональный Документы
Культура Документы
From the Division of Vascular Surgery, Department of Surgery, University of Washington School of Medicine, Seattlea; the Division of
Vascular and Endovascular Surgery, Department of Surgery, Mayo
Clinic, Rochesterb; the Section of Vascular Surgery, Jobst Vascular
Center, Toledoc; the Section of Vascular Surgery, Department of
Surgery, Indiana University School of Medicine, Indianapolisd; Vascular Surgery, University of Lund, Helsingborge; the Division of Vascular
Surgery, Department of Surgery, University of Rochester School of
Medicine & Dentistry, Rochesterf; Lohr Surgical Specialists, Cincinnatig; the Division of Vascular Surgery, Department of Surgery, Southern
Illinois University, Springfieldh; the Department of Preventive, Occupational, and Aerospace Medicine, Mayo Clinic, Rochesteri; the Division of
Vascular Surgery, Department of Surgery, University of Medicine &
Dentistry of New Jersey, Newarkj; the Department of Surgery, The
Brooklyn Hospital Center, New Yorkk; the Division of Vascular Surgery,
Department of Surgery, VA Boston Healthcare System, West Roxburyl;
1449
1450 Meissner et al
Guideline
1.
1.1.
1.2.
2.
2.1.
2.2.
2.3.
3.
3.1.
3.2.
3.3.
4.
4.1.
4.2.
5.
5.1.
5.2.
6.
6.1.
6.2.
Description
Precision in the diagnosis of deep venous thrombosis
We recommend use of precise anatomic terminology to characterize the most
proximal extent of venous thrombosis as involving the iliofemoral veins, with
or without extension into the inferior vena cava; the femoropopliteal veins; or
isolated to the calf veins in preference to simple characterization of a
thrombus as proximal or distal.
If iliofemoral venous thrombosis is suspected but not confirmed using standard
diagnostic modalities such as venous ultrasound imaging, we recommend the
use of adjunctive imaging modalities, such as computed tomography
venography or magnetic resonance venography to characterize the most
proximal thrombus extent.
Indications for early thrombus removal
We suggest a strategy of early thrombus removal in selected patients meeting the
following criteria (a) a first episode of acute iliofemoral deep venous thrombosis,
(b) symptoms 14 days in duration, (c) a low risk of bleeding, and (d)
ambulatory with good functional capacity and an acceptable life expectancy.
We recommend early thrombus removal strategies as the treatment of choice in
patients with limb-threatening venous ischemia due to iliofemoral deep
venous thrombosis with or without associated femoropopliteal venous
thrombosis (phlegmasia cerulea dolens).
We recommend that patients with isolated femoropopliteal deep venous
thrombosis be managed with conventional anticoagulation therapy because
there is currently insufficient evidence to support early thrombus removal
strategies in this patient population.
Techniques for early thrombus removal
We suggest percutaneous catheter-based techniques (pharmacologic or
pharmacomechanical) as first-line therapy for early thrombus removal in
patients meeting the criteria in 1.1.
We suggest a strategy of pharmacomechanical thrombolysis be considered over
catheter-directed pharmacologic thrombolysis alone if expertise and resources
are available.
We suggest open surgical venous thrombectomy in selected patients who are
candidates for anticoagulation but in whom thrombolytic therapy is
contraindicated.
Periprocedural inferior vena cava filters
We recommend against routine use of inferior vena cava filters (permanent or
temporary) in conjunction with catheter-directed pharmacologic thrombolysis
of the iliofemoral venous segments.
We suggest that the relative risks vs benefits of periprocedural retrievable inferior
vena cava filter placement be considered in patients undergoing
pharmacomechanical thrombolysis and those with thrombus extending into
the inferior vena cava or having markedly limited cardiopulmonary reserve.
Adjunctive use of venous stents
We recommend the use of self-expanding metallic stents for treatment of
chronic iliocaval compressive or obstructive lesions that are uncovered by any
of the thrombus removal strategies.
We suggest that stents not be used in the femoral and popliteal veins.
Early thrombus removal strategies as an adjunct to conventional management
We recommend that patients managed with early thrombus removal be treated
with a standard course of conventional anticoagulation after the procedure.
We recommend that all patients be treated with knee-high compression
stockings (30 to 40 mm Hg) for at least 2 years after the procedure.
Grade of
recommendation:
1: Strong
2: Weak
Quality of evidence
A. High
B. Moderate
C. Low or very low
Meissner et al 1451
Grade 2 recommendations are weaker and reflect therapies where the benefits and risks are uncertain or are
more closely balanced. For such interventions, patients
may choose different options based on their underlying values.
1452 Meissner et al
Table. Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to treatment
recommendations
Recommendation
Benefit vs risk
1A
Clear
1B
Clear
1C
Clear
2A
Balanced or unclear
2B
Balanced or unclear
2C
Balanced or unclear
Quality of evidence
High: Consistent results from RCTs or
observational studies with large effects
Moderate: RCTs with limitations and very
strong observational studies
Low: Observational studies
Very low: Case series, descriptive reports,
expert opinion
High: Consistent results from RCTs or
observational studies with large effects
Moderate: RCTs with limitations and very
strong observational studies
Low: Observational studies
Very low: Case series, descriptive reports,
expert opinion
Comment
Strong recommendation, generalizable
Strong recommendation; may change with
further research
Intermediate recommendation; likely to
change with further research
Intermediate recommendation: May vary
with patient values
Weak recommendation: May vary with
patient values
Weak recommendation: Alternative
treatments may be equally valid
Occasional differences regarding the grade of recommendation were resolved through additional review of the
available data, discussion, and formal vote. On adoption of
the final manuscript, there was a maximum of one dissenting opinion regarding the grade of recommendations 2.1
and 6.2.
GUIDELINES
1. Precision in the diagnosis of DVT
1.1. We recommend use of precise anatomic terminology to characterize the most proximal extent of
venous thrombosis as involving the iliofemoral veins,
with or without extension into the inferior vena cava;
the femoropopliteal veins; or isolated to the calf veins in
preference to simple characterization of a thrombus as
proximal or distal (Grade 1A). Based on perceived differences in outcomes, DVT has historically been considered
to involve the proximal veins or as isolated to the distal or
calf veins. On the basis of the most central extent of
thrombosis, proximal venous thrombosis includes femoropopliteal thrombosis and iliofemoral thrombosis. As defined by the Society of Interventional Radiology,26,27 iliofemoral DVT involves complete or partial thrombosis of
the iliac vein or the common femoral vein, or both, with or
without femoropopliteal DVT. Femoropopliteal DVT involves the femoral or popliteal venous segments, or both,
without extension to the common femoral or iliac veins. It
is becoming increasingly clear that the natural history of
femoropopliteal and iliofemoral thrombosis is significantly
different and that simple stratification of treatment according to involvement of the proximal or distal veins is no
longer adequate.
From a pathophysiologic perspective, thrombolytic
studies have shown that iliofemoral venous thrombosis is
associated with a very high incidence of underlying anatomic abnormalities in the iliac veins.16 Compared with
femoropopliteal thrombosis, iliofemoral thrombosis is also
Meissner et al 1453
1454 Meissner et al
rectly to contrast venography in anticipation of intervention. However, further noninvasive imaging of the pelvis
with CTV or MRV should be considered when a clinical
suspicion of DVT persists despite a negative result on an
ultrasound examination. If iliofemoral thrombus is identified, definitive contrast imaging can be performed at the
time of any planned intervention.
Selection of the appropriate study depends on patient
characteristics and institutional expertise. In strongly recommending the use of alternative imaging in such situations, a high value is placed on identifying isolated iliofemoral thrombosis that may be missed by routine ultrasound
imaging, although the cost-effectiveness of this approach
has not been evaluated nor have prospective management
trials been performed (Grade 1C).
2. Indications for early thrombus removal
2.1. We suggest a strategy of early thrombus removal in selected patients meeting the following criteria: (a) a first episode of acute iliofemoral deep venous
thrombosis, (b) symptoms <14 days in duration, (c) a
low risk of bleeding, and (d) ambulatory with good
functional capacity and an acceptable life expectancy
(Grade 2C). The strength of recommendation for strategies of early thrombus removal are based on balancing the
patient-important benefits of prevention of the postthrombotic syndrome and quality of life vs the risks of therapy;
specifically, bleeding, PE, and recurrent DVT. The use of
surrogate outcomes may also be relevant, such as the prevention of venous reflux and persistent venous obstruction,
although they provide a less robust estimate of benefit and
contribute to the indirectness of the evidence. Overall, the
quality of evidence supporting early thrombus removal
strategies is very low (Grade C) because of the methodologic limitations of the relevant studies (lack of randomization, incomparability of study groups, loss to follow-up),
imprecise estimates of effects, and indirectness of the
evidence.19
However, the available evidence does suggest that early
thrombus removal strategies for iliofemoral venous thrombosis are associated with significant reductions in manifestations
of the postthrombotic syndrome as well as improvements in
the surrogate markers of valvular incompetence (reflux) and
persistent venous obstruction.19 Competing risks include those associated with surgery (surgical thrombectomy) and bleeding (thrombolytic strategies). Systematic review of comparative studies suggests that adverse
events are poorly reported overall19 and that caution is
warranted in ensuring patients are appropriately selected.
The balance of risks vs benefits for individual early
thrombus removal strategies are further discussed below.
Less rigorous evidence suggests that the optimal patient population includes patients with a first episode of
iliofemoral DVT of 14 days in duration, having a reasonable life expectancy, and without a high risk of bleeding.
Recommendations regarding the optimal patient population are largely derived from one large, multicenter registry
of patients undergoing catheter-directed pharmacologic
Meissner et al 1455
1456 Meissner et al
well compensated due to axial transformation of the profunda femoris vein through remnants of the axial limb
vein.67
Multicenter registries have further suggested a less
favorable outcome for femoropopliteal than for iliofemoral
DVT treated with thrombolytic therapy.16 Although an
effect of thrombus chronicity cannot be excluded, 1-year
patency was achieved in only 47% of limbs with femoropopliteal thrombosis compared with 64% of limbs with iliofemoral thrombosis. Complete lysis was not achieved in any
patient with femoropopliteal DVT present for 10 days.
Although recommendations may change with the availability of better-quality evidence, there is currently little evidence supporting a role for early thrombus removal strategies in the treatment of femoropopliteal DVT. However,
we must acknowledge that the beneficial effects of early
thrombus removal were not substantially changed if studies
not explicitly evaluating the treatment of iliofemoral DVT
were included in the systematic review.19 This at least raises
the possibility that these strategies may have some role in
the treatment of femoropopliteal DVT.
3. Techniques for early thrombus removal
3.1. We suggest percutaneous catheter-based techniques (pharmacologic or pharmacomechanical) as
first-line therapy for early thrombus removal in patients meeting the criteria in 1.1 (Grade 2C). Compared with standard anticoagulant therapy, catheter-directed pharmacologic thrombolytic therapy is associated
with significant reductions in the risks of the postthrombotic syndrome (relative risk [RR], 0.19; 95% CI .07.48), venous reflux (RR, 0.21; 95% CI, 0.09-0.53), and
venous obstruction (RR, 0.35; 95% CI, 0.17-0.34).19
These results are consistent with a previous systematic
review,20 which included less efficient systemic and locoregional techniques, demonstrating a significant reduction in postthrombotic syndrome (RR, 0.66; 95% CI,
0.47-0.94) with thrombolytic treatment. According to
this review, one case of postthrombotic syndrome would
be prevented for every five patients treated with thrombolytic therapy. The short-term hemodynamic results of
one additional randomized clinical trial in which catheter-directed pharmacologic thrombolysis was compared
with standard anticoagulation has been published since
the most recent systematic review.50 Among 103 randomized patients, 6-month patency was significantly better
in those who received catheter-directed pharmacologic
thrombolysis (64.0% vs 35.8%; P .004), whereas the
incidence of femoral vein reflux was similar (60.0% vs
66.0%; P .53).
Contraindications to thrombolytic therapy include active internal bleeding; recent cerebrovascular accident or
intracranial surgery, trauma, or tumor; recent serious gastrointestinal bleeding; major trauma or surgery 10 days;
severe uncontrolled hypertension; pregnancy; endocarditis;
intracardiac thrombus; known right-to-left shunt; coagulopathy, thrombocytopenia, or absolute contraindications
to anticoagulation; suspected septic thrombus; and allergy
to thrombolytic agents.16,27 Although most contraindications can be identified on routine clinical assessment,
some68 have suggested brain imaging before thrombolysis
in patients with malignancies known to metastasize to the
central nervous system.
The associated risks of catheter-directed thrombolysis
include hemorrhage (particularly intracranial), PE, and recurrent DVT. Although complications have been poorly
reported in comparative trials, some data regarding the
bleeding complications associated with catheter-directed
thrombolytic therapy are available. Among 473 patients
reported in the multicenter National Venous Registry,
bleeding complications were reported in 54 (11%), neurologic complications in two (0.4%), PE in six (1%), and death
in two (0.4%). Bleeding complications were most common
at the venous insertion site (4%) or in the retroperitoneum
(1%). Major neurologic complications, including one fatal
intracranial hemorrhage and one subdural hematoma, occurred in only two patients (0.4%).
A systematic review that included trials of systemic and
locoregional thrombolysis reported higher rates of bleeding among patients treated with thrombolytic agents (RR,
1.73; 95% CI 1.04-2.88) but no significant differences in
mortality (RR, 0.84; 95% CI, 0.29-2.42), pulmonary embolism (RR, 1.23; 95% CI, 0.34-4.45), or intracranial
hemorrhage (RR, 1.70; 95% CI, 0.21-13.70).20 Notably,
these authors observed that bleeding complications, which
occurred in 10% of thrombolytic patients compared with
8% of patients treated with anticoagulation, tended to
decrease over time, perhaps reflecting improved thrombolytic techniques and more rigorous exclusion criteria. Finally, a pooled analysis of 19 studies, largely single-center
case series, reported major bleeding in a mean of 8.3% of
patients (range, 0%-24%) and rates of symptomatic PE,
intracranial hemorrhage, and death of 0.9% (range, 0%1%), 0.2% (range, 0%-1%), and 0.3% (range, 0%-1%),
respectively.27
There are little comparative data evaluating optimal
thrombolytic agents, doses of lytic agents and concurrent
anticoagulants, and infusion techniques. Streptokinase, although rarely used due to the risks of allergic reactions and
bleeding, remains the only thrombolytic agent approved by
the United States Food and Drug Administration for the
treatment of DVT. Several series, however, have reported
the successful use of urokinase,16,69-72 tissue plasminogen
activator,69-71 reteplase,69-71 and tenecteplase73 for venous
thrombolysis.
A consensus panel of the Society of Interventional
Radiology has reviewed recommended thrombolytic dosages and techniques for their catheter-directed administration.68 Because patient characteristics and bleeding risks
vary, individual judgment is required in the selection of
appropriate thrombolytic and concurrent anticoagulant
doses. Most would agree that thrombolytic infusion times
should be minimized and balanced against lytic progress to
avoid complications. Reimaging with follow-up venography at 8- to 24-hour intervals68 and discontinuation of
therapy once lytic stagnation is reached are commonly
Meissner et al 1457
1458 Meissner et al
toward better outcomes with catheter-directed thrombolysis than with thrombectomy with respect to the risk
of the postthrombotic syndrome (RR, 0.33; 95% CI,
0.00-2.28), venous reflux (RR, 0.44; 95% CI, 0.052.10), and venous obstruction (RR, 0.30; 95% CI, 0.012.13).8 We acknowledge that these data suffer from
indirect comparison, wide CIs, and potential confounding by the discordant time intervals during which the
studies were performed.
In recommending the thrombolytic techniques over
surgical thrombectomy in patients who are candidates for
either approach, a higher value is placed on avoiding the
more invasive procedure and potential surgical complications than on unknown differences in bleeding rates. However, given the more invasive nature, the limited experience
of most surgeons, and the potentially greater risk of complications with surgical thrombectomy, the weight of the
evidence would seem to favor percutaneous thrombolytic
approaches over surgical thrombectomy in patients without
contraindications to thrombolytic agents.
5.1. We recommend the use of self-expanding metallic stents for treatment of chronic iliocaval compressive or obstructive lesions that are uncovered by any of
the thrombus removal strategies (Grade 1C). and
5.2. We suggest that stents not be used in the
femoral and popliteal veins (Grade 2C). Acute DVT is
usually regarded as a multicausal disease, arising from the
interaction of multiple genetic, environmental, and behavior risk factors.88,89 The importance of underlying anatomic factors, such as nonthrombotic iliac vein lesions,90
was not appreciated when conventional anticoagulation
was the only therapeutic option. However, with the development of image-guided techniques for early thrombus
removal, including surgical thrombectomy and thrombolytic strategies, it has become clear that compressive or
obstructive iliac vein lesions contribute to many cases of
iliofemoral DVT. A pooled analysis of 19 published studies,
including 1046 patients treated with catheter-directed or
pharmacomechanical thrombolysis, reported the use of
stents in 46% of patients.27 Although the total number of
limbs with stenoses or obstructive lesions uncovered by
lytic therapy in the National Venous Registry was not
reported, 33% of limbs required treatment with metallic
stents.16 The 1-year patency was significantly better in
limbs treated with iliac stents (74%) than in limbs without
stent placement (53%; P .001).
Although lacking evidence from comparative trials, the
relatively poor results associated with untreated iliac stenosis and the poor results achieved with angioplasty favor
stenting of any persistent obstructive lesions uncovered by
thrombolysis and is strongly recommended (Grade 1C).
Single-plane venography may be relatively insensitive in the
detection of iliocaval compression. Compared with intravascular ultrasound, venography has been demonstrated to
have a sensitivity of only 45% for the detection of chronic
iliac obstruction.91 Although likely a useful adjunct in this
setting, there are currently little data regarding the use of
Meissner et al 1459
1460 Meissner et al
REFERENCES
1. Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein
thrombosis in the general population: systematic review. Eur J Vasc
Endovasc Surg 2003;25:1-5.
2. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP,
Van Der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared
with subcutaneous low-molecular-weight heparin administered at
home. The Tasman Study Group. N Engl J Med 1996;334:682-7.
3. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A
comparison of low-molecular-weight heparin administered primarily
at home with unfractionated heparin administered in the hospital for
proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
4. Bller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F,
et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med
2004;140:867-73.
5. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A
meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining
some unanswered questions regarding location of treatment, product
type, and dosing frequency. Arch Intern Med 2000;160:181-8.
6. Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location
of thrombosis determine the risk of disease recurrence in patients with
proximal deep vein thrombosis? Am J Med 2001;110:515-9.
7. Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, et al.
The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997;82:423-8.
8. Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, et al.
Determinants and time course of the postthrombotic syndrome after
acute deep venous thrombosis. Ann Intern Med 2008;149:698-707.
9. Kahn SR. The post-thrombotic syndrome: progress and pitfalls. Br J
Haematol 2006;134:357-65.
10. Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on
health-related quality of life after deep venous thrombosis. Arch Intern
Med 2002;162:1144-8.
11. Johnson BF, Manzo RA, Bergelin RO, Strandness DE. Relationship
between changes in the deep venous system and the development of
the postthrombotic syndrome after an acute episode of lower limb
deep vein thrombosis: A one- to six-year follow-up. J Vasc Surg
1995;21:307-13.
12. Johnson BF, Manzo RA, Bergelin RO, Strandness DE. The site of
residual abnormalities in the leg veins in long-term follow-up after
deep vein and their relationship to the development of the postthrombotic syndrome. Int Angiol 1996;15:14-9.
13. Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH. Pooled analyses
of randomized trials of streptokinase and heparin in phlebographically
documented acute deep venous thrombosis. Am J Med 1984;76:393-7.
14. Schwieder G, Grimm W, Siemens HJ, Flor B, Hilden A, Gmelin E, et
al. Intermittent regional therapy with rt-PA is not superior to systemic
thrombolysis in deep vein thrombosis (DVT)a German multicenter
trial. Thromb Haemost 1995;74:1240-3.
15. Eklof B, Arfvidsson B, Kistner RL, Masuda EM. Indications for
surgical treatment of iliofemoral vein thrombosis. Hematol/Oncol
Clin North Am 2000;14:471-82.
16. Mewissen MW, Seabrook GR, Meissner MH, Cynamon J, Labropoulos N, Haughton SH. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter
registry. Radiology 1999;211:39-49.
17. Karthikesalingam A, Young EL, Hinchliffe RJ, Loftus IM, Thompson
MM, Holt PJ. A systematic review of percutaneous mechanical thrombectomy in the treatment of deep venous thrombosis. Eur J Vasc
Endovasc Surg 2011;41:554-65.
18. Comerota AJ, Throm RC, Mathias SD, Haughton S, Mewissen M.
Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. J Vasc Surg 2000;32:130-7.
19. Casey ET, Munrad MH, Zumeta Garcia M, Elamin MB, Qian S,
Erwin PJ, et al. Treatment of acute iliofemoral deep vein thrombosis:
a systematic review and meta-analysis. J Vasc Surg 2011 [submitted to
J Vasc Surg].
20. Watson LI, Armon MP. Thrombolysis for acute deep vein thrombosis.
Cochrane Database Syst Rev 2004:CD002783.
21. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al;
GRADE Working Group. Grading quality of evidence and strength of
recommendations. BMJ 2004;328:1490-4.
22. Murad MH, Swiglo BA, Sidawy AN, Ascher E, Montori VM. Methodology for clinical practice guidelines for the management of arteriovenous access. J Vasc Surg 2008;48:26S-30S.
23. Guyatt G, Schnemann HJ, Cook D, Jaeschke R, Pauker S. Applying
the grades of recommendation for antithrombotic and thrombolytic
therapy: the Seventh ACCP Conference on Antithrombotic and
Thrombolytic Therapy. Chest 2004;126:179-87S.
24. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota
AJ. Antithrombotic therapy for venous thromboembolic disease:
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:454-545S.
25. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984;74:979-83.
26. Vedantham S, Millward SF, Cardella JF, Hofmann LV, Razavi MK,
Grassi CJ, et al. Society of Interventional Radiology position statement: treatment of acute iliofemoral deep vein thrombosis with use of
adjunctive catheter-directed intrathrombus thrombolysis. J Vasc Interv Radiol 2006;17:613-6.
27. Vedantham S, Thorpe PE, Cardella JF, Grassi CJ, Patel NH, Ferral H,
et al. Quality improvement guidelines for the treatment of lower
extremity deep vein thrombosis with use of endovascular thrombus
removal. J Vasc Interv Radiol 2006;17:435-47.
28. Caps MT, Manzo RA, Bergelin RO, Meissner MH, Strandness DE.
Venous valvular reflux in veins not involved at the time of acute deep
vein thrombosis. J Vasc Surg 1995;22:524-31.
29. Delis KT, Bountouroglou D, Mansfield AO. Venous claudication in
iliofemoral thrombosis: long-term effects on venous hemodynamics,
clinical status, and quality of life. Ann Surg 2004;239:118-26.
30. Hill SL, Martin D, McDannald ER, Jr, Donato AT. Early diagnosis of
iliofemoral venous thrombosis by Doppler examination. Am J Surg
1988;156:11-5.
31. Beyth RJ, Cohen AM, Landefeld CS. Long-term outcomes of deepvein thrombosis. Arch Intern Med 1995;155:1031-7.
32. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al.
The long-term clinical course of acute deep venous thrombosis. Ann
Intern Med 1996;125:1-7.
33. Shields GP, Turnipseed S, Panacek EA, Melnikoff N, Gosselin R,
White RH. Validation of the Canadian clinical probability model for
acute venous thrombosis. Acad Emerg Med 2002;9:561-6.
34. Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, et al.
Value of assessment of pretest probability of deep-vein thrombosis in
clinical management. Lancet 1997;350:1795-8.
35. Anderson DR, Wells PS, Stiell I, MacLeod B, Simms M, Gray L, et al.
Management of patients with suspected deep vein thrombosis in the
emergency department: combining use of a clinical diagnosis model
with D-dimer testing. J Emerg Med 2000;19:225-30.
36. Bucek RA, Koca N, Reiter M, Haumer M, Zontsich T, Minar E.
Algorithms for the diagnosis of deep-vein thrombosis in patients with
low clinical pretest probability. Thromb Res 2002;105:43-7.
37. Dryjski M, OBrien-Irr MS, Harris LM, Hassett J, Janicke D. Evaluation of a screening protocol to exclude the diagnosis of deep venous
thrombosis among emergency department patients. J Vasc Surg 2001;
34:1010-5.
38. Kelly J, Hunt BJ. Role of D-dimers in diagnosis of venous thromboembolism. Lancet 2002;359:456-8.
39. Schutgens RE, Ackermark P, Haas FJ, Nieuwenhuis HK, Peltenburg
HG, Pijlman AH, et al. Combination of a normal D-dimer concentration and a non-high pretest clinical probability score is a safe strategy to
exclude deep venous thrombosis. Circulation 2003;107:593-7.
40. Kearon C, Julian JA, Math M, Newman TE, Ginsberg JS. Noninvasive
diagnosis of deep venous thrombosis. McMaster diagnostic imaging
practice guidelines initiative. Ann Intern Med 1998;128:663-77.
41. Messina LM, Sarpa MS, Smith MA, Greenfield LJ. Clinical significance
of routine imaging of iliac and calf veins by color flow duplex scanning
Meissner et al 1461
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
1462 Meissner et al
66. Modrall JG, Hocking JA, Timaran CH, Rosero EB, Arko FR 3rd,
Valentine RJ, et al. Late incidence of chronic venous insufficiency after
deep vein harvest. J Vasc Surg 2007;46:520-5.
67. Raju S, Fountain T, Negln P, Devidas M. Axial transformation of the
profunda femoris vein. J Vasc Surg 1998;27:651-9.
68. Vedantham S, Thorpe PE, Cardella JF, Grassi CJ, Patel NH, Ferral H,
et al. Quality improvement guidelines for the treatment of lower
extremity deep vein thrombosis with use of endovascular thrombus
removal. J Vasc Interv Radiol 2009;20:S227-39.
69. Protack CD, Bakken AM, Patel N, Saad WE, Waldman DL, Davies
MG. Long-term outcomes of catheter directed thrombolysis for lower
extremity deep venous thrombosis without prophylactic inferior vena
cava filter placement. J Vasc Surg 2007;45:992-7.
70. Vedantham S, Vesely TM, Parti N, Darcy M, Hovsepian DM, Picus D.
Lower extremity venous thrombolysis with adjunctive mechanical
thrombectomy. J Vasc Interv Radiol 2002;13:1001-8.
71. Lin PH, Zhou W, Dardik A, Mussa F, Kougias P, Hedayati N, et al.
Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous
thrombosis. Am J Surg 2006;192:782-8.
72. Kim HS, Patra A, Paxton BE, Khan J, Streiff MB. Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein
thrombosis: clinical and economic outcomes. J Vasc Interv Radiol
2006;17:1099-104.
73. Arko FR, Davis CM, 3rd, Murphy EH, Smith ST, Timaran CH, Modrall
JG, et al. Aggressive percutaneous mechanical thrombectomy of deep
venous thrombosis: early clinical results. Arch Surg 2007;142:513-8.
74. Dasari TW, Pappy RM, Hennebry TA. Pharmacomechanical thrombolysis of acute and chronic symptomatic deep vein thrombosis: a
systematic review of literature. Angiology 2012;63:138-45.
75. Fasolini FG, Streuli HK. [Thrombectomy versus conservative therapy
of thrombosis of the deep veins of the pelvis and legs. Late results 10
years later]. Helv Chir Acta 1985;52:735-8.
76. Gnger KH, Nachbur BH, Ris HB, Zurbrgg H. Surgical thrombectomy
versus conservative treatment for deep venous thrombosis; functional
comparison of long-term results. Eur J Vasc Surg 1989;3:529-38.
77. Hamilton H, Pontin AR, Immelman EJ, Kahn D. Venous thrombectomy in patients presenting with iliofemoral vein thrombosis after
renal transplantation. Transpl Int 1996;9:513-6.
78. Hold M, Bull PG, Raynoschek H, Denck H. Deep venous thrombosis:
results of thrombectomy versus medical therapy. Presented at the 5th
European-American Symposium on Venous Diseases, Vienna, Austria,
November 7-11, 1990. VASA; 1992;21:181-7.
79. Matsubara J, Ban I, Nakata Y, Shinjo K, Hirai M, Miyazaki H.
Long-term follow-up results of the iliofemoral venous thrombosis.
J Cardiovasc Surg (Torino) 1976;17:234-9.
80. Plate G, Einarsson E, Ohlin P, Jensen R, Qvarfordt P, Eklf B. Thrombectomy with temporary arteriovenous fistula: the treatment of choice in
acute iliofemoral venous thrombosis. J Vasc Surg 1984;1:867-76.
81. Sato S, Iwai T, Sakurazawa K, Inoue Y, Takiguchi N, Sugano N, et al.
[Conservative treatment of acute deep vein thrombosis of lower extremities]. Nihon Geka Gakkai Zasshi. 1992;93:1052-4.
82. Stiegler H, Arbogast H, Halder A, Grau A, Riess H, Tosch U.
[Operation, lysis, heparin therapy: 3 equally valid forms of therapy in
acute leg-pelvic venous thrombosis]. Vasa Suppl 1987;20:153-6.
83. Trngren S, Hjertberg R, Rosfors S, Bremme K, Eriksson M, Swedenborg J. The long-term outcome of proximal vein thrombosis during
pregnancy is not improved by the addition of surgical thrombectomy
to anticoagulant treatment. Eur J Vasc Endovasc Surg 1996;12:31-6.
84. Eklof B, Kistner RL. Is there a role for thrombectomy in iliofemoral
venous thrombosis? Semin Vasc Surg 1996;9:34-45.
85. Klbel T, Alhadad A, Acosta S, Lindh M, Ivancev K, Gottster A.
Thrombus embolization into IVC filters during catheter-directed
thrombolysis for proximal deep venous thrombosis. J Endovasc Ther
2008;15:605-13.
86. Martinez Trabal JL, Comerota AJ, LaPorte FB, Kazanjian S, DiSalle R,
Sepanski DM. The quantitative benefit of isolated, segmental, phar-
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.